The ability to anchor chemical class-based gene expression changes to phenotypic lesions and to describe these changes as a function of dose and time informs mode-of-action determinations and improves quantitative risk assessments. Previous global expression profiling identified a 330-probe cluster differentially expressed and commonly responsive to 3 hepatotumorigenic conazoles (cyproconazole, epoxiconazole, and propiconazole) at 30 days. Extended to 2 more conazoles (triadimefon and myclobutanil), the present assessment encompasses 4 tumorigenic and 1 nontumorigenic conazole. Transcriptional benchmark dose levels (BMDL T ) were estimated for a subset of the cluster with doseresponsive behavior and a ≥ 5-fold increase or decrease in signal intensity at the highest dose. These genes primarily encompassed CAR/RXR activation, P450 metabolism, liver hypertrophyglutathione depletion, LPS/IL-1-mediated inhibition of RXR, and NRF2-mediated oxidative stress pathways. Median BMDL T estimates from the subset were concordant (within a factor of 2.4) with apical benchmark doses (BMDL A ) for increased liver weight at 30 days for the 5 conazoles. The 30-day median BMDL T estimates were within one-half order of magnitude of the chronic BMDL A for hepatocellular tumors. Potency differences seen in the dose-responsive transcription of certain phase II metabolism, bile acid detoxification, and lipid oxidation genes mirrored each conazole's tumorigenic potency. The 30-day BMDL T corresponded to tumorigenic potency on a milligram per kilogram day basis with cyproconazole > epoxiconazole > propiconazole > triadimefon > myclobutanil (nontumorigenic). These results support the utility of measuring short-term gene expression changes to inform quantitative risk assessments from long-term exposures.
Toxicological characterization of the approximately 80,000 chemicals in commerce using the traditional battery of toxicology studies, including the rodent bioassay for predicting carcinogenicity, is not economically or technologically feasible (NRC, 2007a) . A chronic bioassay requires up to 5 years and $2-$4 million per chemical (Manuppello and Willett, 2008) . From a tactical standpoint, risk assessment approaches that integrate existing knowledge with emerging technologies will advance testing strategies, improve the utility and predictability of risk assessment methods, and reduce the environmental and human health impact of chemicals while maximizing their economic value (Dellarco et al., 2010; U.S. EPA, 2011a) .
The National Academies of Sciences (NRC, 2007a (NRC, ,b, 2009 ) proposed a strategy for reduced reliance on animal testing and greater efficiency in risk assessment by adopting newer toxicogenomic approaches. Because molecular changes precede clinical or phenotypic (ie, apical) effects, genomic changes after short-term chemical exposure may inform longer term effects at lower, more environmentally relevant exposures. To date, the application of more modern technologies has been largely qualitative, such as discerning rodent liver or lung carcinogens from noncarcinogens (Auerbach et al., 2010; Ellinger-Ziegelbauer et al., 2008; Thomas et al., 2007a) ; phenobarbital-like carcinogens from peroxisome proliferator hepatocarcinogens (Hamadeh et al., 2002) ; and genotoxic from nongenotoxic hepatocarcinogens (Fielden et al., 2011) . These methods are useful screening and prioritization tools and can also inform chemical mode-of-action (MOA) determinations used to assess human health relevance. When used in conjunction with doseresponse information, genomic data can also inform relative potency for agents acting through a particular MOA, such as the 50% effective dose (ED 50 ) for aryl hydrocarbon receptor activation by dioxin-like compounds (Kopec et al., 2010) or phthalate-induced male reproductive developmental toxicity (Hannas et al., 2012) .
Most quantitative cancer or noncancer risk assessments require a low-dose point of departure (POD), such as a 10% effective dose (ED 10 ) for the most sensitive adverse effect, to subsequently derive acceptable exposure levels. The benchmark toxicological sciences 136(1), 205-215 2013 doi:10 .1093/toxsci/kft182 Advance Access publication August 22, 2013 dose (BMD) approach is the preferred method for identifying a low-dose POD because it considers the entire range of the experimental data as opposed to one of the experimental doses being identified as the no-observed or lowest-observed-adverse-effect level (NOAEL or LOAEL, respectively) . NOAEL and LOAEL values are influenced by sample size and dose spacing and do not consider the slope or shape of the dose-response curve (Davis et al., 2011; U.S. EPA, 2002 U.S. EPA, , 2005 U.S. EPA, , 2012a . Further, there may be fundamental differences in the biological response (ie, dose transitions) at different parts of the dose-response curve for lesion induction (Slikker et al., 2004) .
Use of genomic data from shorter term exposures to identify critical molecular effects and a POD for quantitative risk assessment of chronic exposure will require dose-response and time-course information for key molecular events and knowledge of how these changes quantitatively relate to apical toxicity endpoints that have traditionally served as the basis of chemical regulation (Ankley et al., 2010; Edwards and Preston, 2008; Paules, 2003) . Whole-genome microarray methods provide both a discovery engine for identifying early key events in a chemical MOA and an information base for MOA-based risk assessment (Edwards and Preston, 2008) . The desire for genomic data to complement dose-response assessments of traditional endpoints (Chiu et al., 2010) is facilitated by the BMDExpress program (Thomas et al., 2007b , Yang et al., 2007 , which accommodates whole-genome microarray data for probe-level dose-response modeling and low-dose extrapolation.
Conazoles are a class of fungicides with agricultural and pharmaceutical applications. Some conazoles, such as cyproconazole, epoxiconazole, propiconazole, and triadimefon, induce hepatocellular tumors in mice but with varying potencies and tumor profiles (Bomhard and Hahnemann, unpublished data; Gerspach, unpublished data; Mellert, unpublished data; Warren et al., unpublished data) . Conversely, myclobutanil was not tumorigenic in mice (Anderson et al., unpublished data-based on California Department of Food and Agriculture, 2000; Goldman and Harris, unpublished data-INCHEM, 1992 and California Department of Food and Agriculture, 2000) . Traditional toxicity endpoints could not distinguish myclobutanil from propiconazole or triadimefon after 30 days of exposure, but some aspects of their gene expression profiles were distinct (Ward et al., 2006) . Similarly, global expression profiling found that cyproconazole, epoxiconazole, and propiconazole had 330 differentially expressed probe sets in common after 30 days of dietary exposure at the highest (ie, a tumorigenic) dose (Hester et al., 2012) . By encompassing 4 tumorigenic and 1 nontumorigenic conazole, this study proposed that the 330-probe highdose signature could be extended to estimate transcriptional benchmark dose levels (BMDL T ) for dose-related probe sets and that this refined low-dose signature could help discern a tumorigenic from a nontumorigenic conazole at 30 days. We also compared the dose and time-course concordance of transcriptional and apical BMD levels at 30 days (ie, phenotypic anchoring) and at 2 years to identify the magnitude of transcriptomic-tophenotypic extrapolation uncertainty, another crucial element in toxicogenomic-driven quantitative risk assessment.
MATERIALS AND METhoDS
The chemical substance characterization and animal exposure protocols have been described previously Hester et al., 2012; Nesnow et al., 2009; Ward et al., 2006) . Briefly, these studies were comparatively designed to assess traditional liver endpoints such as liver weight, hepatic microsomal enzyme induction, and liver histopathology as well as global gene expression in the liver with Affymetrix mouse 430 2.0 whole genome arrays after 30 days of dietary exposure to 5 conazoles in male CD-1 mice, the more sensitive sex. Microarray processing and normalization procedures have been described previously using Rosetta Resolver software (Hester et al., 2012; Nesnow et al., 2009 ). The 30-day studies were conducted in the same facility (U.S. EPA National Health and Environmental Effects Research Laboratory, Research Triangle Park, North Carolina). Liver gene expression was assessed in 5 mice per dose for cyproconazole and epoxiconazole and 3 mice per dose for propiconazole, triadimefon, and myclobutanil. Three dose levels and a concurrent control were included, and the highest dose for cyproconazole (200 ppm), epoxiconazole (500 ppm), and triadimefon (1800 ppm) was the tumorigenic dose in 18-month feeding studies (Bomhard and Hahnemann, unpublished data; Mellert, unpublished data; Warren et al., unpublished data) . The highest dose for propiconazole (2500 ppm) was based on a 24-month feeding study (Hunter et al., unpublished data) . However, in order to be consistent with the chronic exposure duration for the other 4 conazoles, BMD estimates for liver tumors for propiconazole in this study were based on the observed incidences from an 18-month study in which the highest dose of 850 ppm was also tumorigenic (Gerspach, unpublished data). The highest dose for myclobutanil in this study was 2000 ppm. Myclobutanil was tested at up to 2000 ppm in an 18-month feeding study and was not found to be tumorigenic (Anderson et al., unpublished data-based on California Department of Food and Agriculture, 2000) .
Transcriptional BMD estimation. In the present assessment, transcriptional benchmark dose levels (BMDL T ) for liver gene expression were estimated with BMDExpress software (version 1.4.1, 2012) as described by Thomas et al. (2007b) and Yang et al. (2007) with some modifications. The primary modifications were the following: (1) rather than global gene expression, the doseresponse assessment was restricted to the 330-probe differentially expressed gene (DEG) cluster proposed as a 30-day tumorigenicity signature that was previously derived from a global profile (Hester et al., 2012) . (2) IPA software (Ingenuity Pathway Analysis, Ingenuity Systems, www.ingenuity.com) was used for functional annotation because the preconfigured KEGG database is no longer updated. (3) A high-dose fold change (FC) cutoff of 5 (induced or repressed) was ultimately applied based on considerations explained in the Results.
The estimated consumed dose (mg/kg-day) served as the dose metric for each conazole. Normalized linear signal intensities for each probe set were fit to Hill, power, linear (1°), and polynomial (2°) dose-response models. Each model was run assuming constant variance, and the benchmark response factor was set to 1.349 of the control group SD. This represents 11% change in signal intensity tail area due to allowance for a 1% change (0.5% in each tail) to occur in the absence of exposure (Thomas et al., 2007b; Yang et al., 2007) . This 10% change in transcriptional response either up-or downregulated over background (ie, controls) is intended to represent the dose at which transcription is altered above or below background and to be analogous to the 10% benchmark dose level (BMD 10 ) for quantal data, such as histopathology lesions or tumor incidence and also to "1 control standard deviation" above or below the background benchmark response (BMD 1SD ) for continuous data, such as altered liver weight or liver enzymes (U.S. EPA, 2012a). For best-fit model selection, a nested likelihood ratio test was performed on the linear and polynomial 2° models. If the more complex model provided a significantly improved fit (p < .05), the more complex model was selected. The simpler model was selected if the 206 CONAZOLE TRANSCRIPT AND APICAL DOSE RESPONSE more complex model did not provide a significantly improved fit. Similar to apical BMD guidelines (U.S. EPA, 2012a), models with a global goodness-of-fit p values < .1 were excluded; p values of 1 indicate a perfect fit (ie, the model's predicted response is identical to the observed response). To select the best globally fitting model with the least complexity, the Akaike Information Criterion (AIC is −2L + 2p, where L is the log-likelihood at the maximum likelihood estimates [MLEs] for p estimated parameters), for the selected polynomial model was then compared with the AIC for the Hill and power models. The model with the lowest AIC was selected as the final model. In cases where the ''k'' slope parameter for the Hill model was out of bounds, the Hill model was excluded from the final selection. Unacceptable fits were considered probe sets with a BMD T value greater than the highest dose or a global goodness-of-fit p value < .1 and thus were excluded. Descriptive statistics for each conazole were based on the lower 95% confidence limit (BMDL T ) of the BMD T from the best-fitting model.
The remainder of the transcriptional dose-response analysis focused on the 330 probe sets previously reported as being commonly responsive to 3 hepatotumorigenic conazoles (cyproconazole, epoxiconazole, and propiconazole) (Hester et al., 2012) . Briefly, the GeneChip.cel files were normalized and statistically analyzed using Rosetta Resolver software with ANOVA followed by application of the Benjamini-Hochberg false discovery test (p < .05). The DEG lists from the high-dose carcinogenic feed levels of cyproconazole (200 ppm), epoxiconazole (500 ppm), and propiconazole (2500 ppm) were used in a Venn analysis to identify a set of 330 probe sets common to the 3 hepatocarcinogenic conazoles. The myclobutanil and triadimefon transcriptional responses were also processed, normalized, and statistically analyzed using Rosetta Resolver software with ANOVA followed by application of the Benjamini-Hochberg false discovery test (p < .05) from the .cel files described in the study by Ward et al. (2006) .
In the present assessment, the 330 probe set IDs mapped to 281 unique genes based on their NCBI Entrez Gene ID; when more than 1 probe mapped to the same gene, the highest intensity probe was selected for dose-response analysis. Given background variability, in order to exclude non-dose related or only modestly responsive probes, only probes with a normalized FC in signal intensity at the high dose (ie, the tumorigenic dose) of ≥ 5-fold (induced or repressed) were included in the BMDL T descriptive statistics. Dose-responsive behavior was difficult to discern when the high-dose FC was < 5 (described in Results section).
Apical BMD estimation for liver tumors and precursor liver effects. Apical effects are clinical or morphologic effects such as increased liver weight or liver tumors that have more traditionally served as the basis of low-dose quantitative risk assessment. Increased mean relative liver weight and pentoxyresorufin depentylase activity (PROD) at 30 days were modeled based on published data Hester et al., 2012) using mean consumed dose (mg/kg-day) as the dose metric. The lower 95% confidence interval for the response at 1 control standard deviation was used to define these benchmark responses (BMDL 1SD ). Liver weight was assessed in 10-16 mice per dose for each of the 5 conazoles, and PROD was assessed in 4 mice per dose for propiconazole, triadimefon, and myclobutanil. PROD activity measures the O-dealkylation of pentoxyresorufin to resorufin in vitro (Lubet et al., 1985) and represents Cyp2b10 protein induction mediated via activation of the xenobiotic-metabolizing nuclear receptor constitutive androstane receptor (CAR) in mice (Ross et al., 2010) .
The liver tumor benchmark dose (BMDL 10 ) was estimated for hepatocellular adenomas, carcinomas, and the combined incidence of hepatocellular adenoma or carcinoma observed in male mice, the more sensitive sex, after chronic dietary exposure for approximately 18 months to cyproconazole (Warren et al., unpublished data-based on Peffer, 2011 and U.S. EPA, 1990), epoxiconazole (Mellert, unpublished data-based on U.S. EPA, 2001), propiconazole (Gerspach, unpublished data-based on Dewhurst and Dellarco, 2004) , or triadimefon (Bomhard and Hahnemann, unpublished data-based on Dewhurst and Dellarco, 2004) . Myclobutanil was not tumorigenic after chronic dietary exposure (Anderson et al., unpublished data-based on California Department of Food and Agriculture, 2000) . The lower 95% confidence interval of the dose estimated to result in a 10% increase in tumor incidence above background (ie, controls) was used to define the tumor benchmark response (BMDL 10 ). Thus, BMDL 10 values were not estimated when the rate at the highest dose group was less than 10%, which occurred at times when adenomas or carcinomas were evaluated separately (see Table 4 ). The 5 factors collectively taken into consideration for selecting the best-fit model included the global goodnessof-fit p value (must be ≥ .1 but highest value preferred); lowest AIC value, Chi-square residual values of less than 2 at each dose level, visual fit, and the margin between the BMD 10 and BMDL 10 (U.S. EPA, 2012a). Individual animal data were not available to account for reduced survival observed for 1 of the 5 conazoles, propiconazole. A mortality-adjusted BMDL could be lower, recognizing that other factors, such as goodness-of-fit, also contribute to estimated BMDL levels. The best-fit BMDL 1SD model for increased relative liver weight at 30 days and the BMDL 10 for hepatocellular tumors after chronic exposure were compared with the 30-day median BMDL T estimates for each conazole.
RESuLTS

Transcriptional BMD Estimates
The BMDL T values were estimated for the 330 probe sets (281 genes) that comprise the conazole hepatotumorigenicity signature at 30 days. These BMDL T values were intended to reflect the dose at which transcription is altered above or below background (ie, controls) in an approach analogous to apical benchmark dose levels (BMDL A ) for traditional data. In initial studies, generally poor modeling results, such as low goodnessof-fit p values or poor visual fits were obtained for probes having a normalized FC in signal intensity of < 5 at the high dose. This tended to encompass probes that had modest or no change in signal intensity across increasing dose levels, particularly at the low and intermediate dose levels (Supplementary Table S1 ). When identifying DEGs, the greatest source of variability that accounts for high false-negative (ie, low sensitivity) rates occurs for DEGs with low intensity signals and small fold changes (Choe et al., 2005) . Thus, an important feature of a successful microarray analysis is to account for probe sets with low signal intensity, such as by filtering them from the analysis (Choe et al., 2005) . Consequently, it was concluded that dose-response behavior that would permit reliable low-dose extrapolation was not clearly discernible when the high-dose FC was less than 5, and as a result, a FC "cutoff" for inclusion was established at 5.0. Probe sets within the 330-probe cluster with a FC < 5 at the high dose (ie, tumorigenic dose) were excluded from further dose-response analyses.
Of the 330 probes, there were 48 probes (mapping to 45 Entrez genes) considered to have dose-responsive behavior at 30 days because they had a FC ≥ 5 at the high dose for at least 1 conazole (Table 1 ). The number of probes that had an acceptable statistical BMDL T fit ranged from 19 of 48 for myclobutanil to 38 of 48 for propiconazole (Supplementary Table S2 ). The 48 probes primarily encompassed pathways associated with CAR/RXR activation, P450 metabolism, glutathione depletion-hepatocellular hypertrophy, LPS/IL-1-mediated inhibition of RXR function, and NRF2-mediated oxidative stress response according to IPA Tox Lists, a pathway library based on sets of genes known to be perturbed upon compound treatment and that eventually result in measurable pathology 207 (Table 1) . Box and whisker plots illustrate the range of BMDL T estimates and suggest relatively low variability in the modeled genes for each conazole (Fig. 1) . More notably, the range of BMDL T estimates can inform potency for the 5 conazoles with respect to the 30-day conazole hepatotumorigenicity signature. Cyproconazole was the most potent conazole based on the lowest median BMDL T of 9 mg/kg-day, and myclobutanil was the least potent, with the highest median BMDL T of 78 mg/ kg-day. Myclobutanil, the nontumorigenic conazole, also had a statistical lower outlier, which was the BMDL T of 6.9 mg/ kg-day for Cyp2b10. Traditional subchronic toxicity endpoints could not distinguish myclobutanil from tumorigenic conazoles at 30 days because myclobutanil is also associated with doserelated increases in liver weight, Cyp2b10 induction, increased PROD activity, hepatic cell proliferation, and hepatic hypertrophy but not liver tumors in mice Anderson et al., unpublished data-based , 2000) . Thus, not all CAR-activating xenobiotics lead to rodent liver tumors, and this chemical class-based BMDL T approach considered the BMDL T for Cyp2b10 transcription at 30 days to be a distinction between a nontumorigenic CAR agonist and 4 tumorigenic CAR agonists.
On a direct gene-to-apical outcome basis, a high degree of direct concordance was found between BMDL T estimates for Cyp2b10 gene expression and BMDL A estimates for Cyp2b10 protein expressed as PROD activity for 3 conazoles for which data were available, 2 tumorigenic (propiconazole and triadimefon) and 1 nontumorigenic (myclobutanil) conazole ( Fig. 2; Table 2 ). CAR activation has been proposed as the molecular-initiating (ie, first key) event in a MOA sequence culminating in rodent liver tumors (U.S. EPA, 2011b). Because Cyp2b10 is a target gene of CAR activation in mice (Ross et al., 2010) , we propose that our BMDL T values for Cyp2b10 can be viewed as a measure of potency for CAR activation in mice. Further, we observed quantitative concordance, thus anchoring these BMDL T to their apical BMDL A for Cyp2b protein (via PROD measurements) at 30 days. However, the BMDL T for Cyp2b10 gene or protein alone was insufficient to Note. See Supplementary Table S1 for signal intensity fold-change values across dose levels.
*Genes with an asterisk are repressed by FC ≥ 5 and genes without an asterisk are induced by FC ≥ 5 in the 330-probe cluster for at least 1 conazole at the highest dose. distinguish myclobutanil from tumorigenic conazoles based on Table 2 .
Further, with respect to phenotypically anchoring conazolespecific gene expression signatures, 30-day median BMDL T estimates from the 48-probe subset (excluding those with unacceptable fits and/or with a high-dose FC < 5) were concordant (within a factor of 2.4) with apical benchmark doses (BMDL A ) for increased liver weight at 30 days for the 5 conazoles (Table 3; Supplementary Table S3 ). This concordance of 30-day BMDL T with the 30-day BMDL A for increased liver weight is mechanistically supported by CAR/RXR activation, P450 metabolism, and glutathione depletion-hepatocellular hypertrophy being the primary biological pathways represented in the 45 dose-related genes comprising the 30-day hepatotumorigenicity signature. Although centrilobular and panlobular hepatocellular hypertrophies, and at times cytoplasmic vacuolation, were observed after 30 days of dietary exposure to some of the conazoles Hester et al., 2012) , BMD levels were not estimated due to their steep dose responses and small sample sizes (n = 5) included for histological examination. Further, because the BMDL for incidence data is estimated at the 10% response level (U.S. EPA, 2012a) and the minimum sample size that can observe a 10% response is 10 (1 out of 10 animals affected), the sample sizes of 5 would estimate BMDL values outside of the power of detection. However, the sample sizes of 10-16 were adequate for modeling liver weight because BMDL estimates for continuous data are based on the standard deviation of the control group rather than a 10% increase (U.S. EPA, 2012a).
Potency differences in the dose-responsive transcription of some genes, such as those involved in phase II metabolism, bile acid detoxification, or lipid oxidation, including Gstm3, Gstt3, Abcc4, Akr1b7, and Lcn13, tended to mirror the tumorigenic potency gradient. For example, the BMDL T estimates for Akr1b7 were 8, 16, and 51 mg/kg-day for cyproconazole, epoxiconazole, and propiconazole, respectively (Fig. 3) . Whereas transcription of Akr1b7 was not dose related for the weak tumorigen, triadimefon, or the nontumorigen, myclobutanil, based on FC values of ≤ 5 (induced or repressed) at the highest tested dose. The aldo-keto reductase Akr1b7 gene is a common transcriptional target of the CAR and pregnane X receptor family of xenobiotic receptors (Liu et al., 2009) and plays a crucial role in bile acid metabolism and detoxification (Schmidt et al., 2011) . The upregulation of Akr1b7 has been implicated in oxidative stress (Jia et al., 2006; Volat et al., 2012) . Similarly, potency differences in the repressed transcription of the lipid oxidation gene lipocalin 13 (Lcn13) at 30 days tended to mirror the tumorigenic potency gradient. BMDL T estimates for Lcn13 were 16, 21, 31, and 104 mg/kg-day for cyproconazole, propiconazole, triadimefon, and myclobutanil, respectively. At the FIg. 2 . The graphical output of (A) transcriptional and (B) apical (ie, protein) benchmark dose (BMD T and BMD A , respectively) modeling and corresponding 95% lower confidence limit benchmark dose (BMDL T and BMDL A , respectively) for PROD (pmol resorufin formed/min/mg microsomal protein) for propiconazole is shown. The estimates for triadimefon and myclobutanil were also concordant (see Table 2 ; graphs not shown). The models were based on the data reported by Allen et al. (2006) and Hester et al. (2012) . No data were available for PROD measurements at 30 days for cyproconazole or epoxiconazole. Abbreviation: PROD, pentoxyresorufin depentylase activity. 
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highest dose, the decreases in FC values ranged from −8 to −22 for these 4 conazoles. Although also repressed for epoxiconazole (FC of up to −8 at the highest dose), the BMDL T result for Lcn13 for epoxiconazole was an unacceptable fit (ie, BMD > highest dose) and thus excluded. Potency gradients at 30 days that mirrored tumorigenic potency were also observed for 2 unannotated probe sets, 1443137_at and 1438068_at. These probe sets were retained in the analysis because they were considered bioindicators of dose-responsive transcription for the 5 conazoles at 30 days, while recognizing that their potential biological or functional relevance is currently unknown. The BMDL T estimates for the 1443137_at probe set were 3, 4, 9, 12, and 30 mg/kg-day for cyproconazole, epoxiconazole, propiconazole, triadimefon, and myclobutanil, respectively. Similarly, BMDL T estimates for the 1438068_at probe set were 10, 30, 35, 62, and 82 mg/kg-day for the same conazoles.
Chronic Apical BMD Estimates
Chronic apical BMDL 10 values were estimated for hepatocellular adenomas, hepatocellular carcinomas, and for the combined incidence of adenomas or carcinomas observed in male mice after chronic (ie, 18 months) dietary exposure to the 4 tumorigenic conazoles (cyproconazole, epoxiconazole, propiconazole, and triadimefon). The chronic study details Note.
a Dose-responsive genes from the conazole subset. b Based on data of Allen et al. (2006) and Hester et al. (2012) . c BMDL A refers to increased mean relative liver weight with the benchmark response set to 1 control group SD according to U.S. EPA (2012a) guidelines.
FIg. 3.
The 30-day BMDL T for some genes mirrored the tumorigenic potency gradient. For example, the transcriptional benchmark doses (BMD T ) and corresponding 95% lower confidence limit benchmark doses (BMDL T ) for the Akr1b7 gene for (A) cyproconazole, (B) epoxiconazole, and (C) propiconazole are shown. Triadimefon and myclobutanil (weakly tumorigenic and nontumorigenic, respectively) had a FC ≤ 5 for Akr1b at the highest dose thus were excluded. The models were based on data of Hester et al. (2012) and Ward et al. (2006) . Abbreviation: FC, fold change. and the incidence data used for BMD modeling are presented in Table 4 . In addition to potency differences, the liver tumor profiles varied to some degree, as cyproconazole was primarily associated with adenomas and epoxiconazole was primarily associated with carcinomas. Triadimefon was only associated with hepatocellular adenomas.
The BMDL 10 values for hepatocellular tumors, particularly for the combined incidence of adenoma or carcinoma, suggested different potencies with cyproconazole > epoxiconazole > propiconazole > triadimefon > myclobutanil (nontumorigenic) ( Table 5 ). The 30-day median BMDL T estimates correctly stratified these 5 conazoles according to tumorigenic potency on a milligram per kilogram day basis and were within one-half order of magnitude of the chronic BMDL A for the combined incidence of hepatocellular adenoma or carcinoma, which are conventionally combined for quantitative risk assessment purposes.
DISCuSSIoN
The present assessment refined the previously proposed 30-day high-dose gene signature (Hester et al., 2012) by estimating low-dose transcriptional BMDL T for dose-related probes. We used this refined signature to help differentiate 4 tumorigenic conazoles from a nontumorigenic conazole after 30 days of exposure and compare the dose and time-course concordance of BMDL T and BMDL A at 30 days (ie, phenotypic anchoring) and at 18 months. Chemical class-based approaches to risk assessment not only foster efficiency compared with a substance-by-substance evaluation but also help identify patterns within a category, increase confidence in the results, and contribute to the weight of evidence (OECD, 2007) .
Because profiling global gene expression is a powerful tool to elucidate toxicant modes of action (Edwards and Preston, 2008) , by focusing on the 330-probe cluster and further reducing it to 48 probes, potentially valuable mechanistic information may have been lost from our analysis. For example, in addition to CAR activation, CYP51 inhibition has been proposed as an additional initial key event in the MOA of propiconazole leading to altered cholesterol homeostasis and increased cell proliferation (Nesnow, 2013) . Cholesterol-related genes in our analysis had low intensity signals and were less dose responsive compared with the CAR-related genes in our analysis. Previous studies with global expression profiling have been used primarily in a qualitative fashion to improve the mechanistic understanding of liver tumor formation (reviewed by U.S. EPA, 2011b). These Note.
a Control rate up to rate in highest modeled dose group, respectively. Italicized rates (adenomas for epoxiconazole; carcinomas for cyproconazole and propiconazole) were not modeled because a < 10% increase above controls was seen in the highest treated group (see Materials and Methods). earlier studies lacked quantitative dose-response information and low-dose potency estimates (ie, BMDLs) for the gene expression and apical toxicity endpoints that were assessed in parallel. Also missing from these studies was a concordance analysis of the data that could contribute to the weight of evidence for key events in the proposed MOA. Our studies generated quantitative dose-response information allowing both low-dose potency estimates and concordance values for the data to be identified. In terms of potency and mechanism, we identified conazolespecific dose-related patterns in liver gene expression at 30 days that are consistent with early, proposed molecular and phenotypic key events in the conazole MOA pathway. As indicated above, BMDL T values for Cyp2b10 as a measure of potency for CAR activation alone did not correctly stratify the 5 conazoles according to tumorigenic potency. Similarly, BMDL 1SD values for increased relative liver weight did not correctly stratify the 5 conazoles. However, our median BMDL T values for the 48-probe dose-related subset from the 30-day tumorigenicity signature correctly stratified these 5 conazoles according to tumorigenic potency. A challenge to incorporating toxicogenomic technologies into the current risk assessment paradigm has been the functional interpretation of genomic data-the linking of potentially related gene expression alterations to conventional, more well-established toxicological endpoints (Hamadeh et al., 2002; Paules, 2003; Yu et al., 2006) .
Following CAR activation, a molecular-initiating event, a first phenotypic key event in conazole hepatotumorigenicity has been proposed to be hepatic hypertrophy (U.S. EPA, 2011b). Other downstream key events such as oxidative stress, increased cell proliferation, and suppression of apoptosis ultimately contribute to tumor induction (Nesnow, 2013; U.S. EPA, 2011b) . Because Cyp2b10 is a target gene of CAR activation in mice (Ross et al., 2010) , we believe that our BMDL T values for Cyp2b10 can be viewed as a quantitative measure of potency for CAR activation in mice. Further, the BMDL A for Cyp2b protein measured via PROD activity at 30 days was a quantitatively concordant apical anchor for Cyp2b10 based on companion data for 3 conazoles (propiconazole, triadimefon, and myclobutanil). The higher median BMDL T estimate for myclobutanil compared with the tumorigenic conazoles suggests that transcription of conazole-induced genes associated with hepatotumorigenesis at 30 days is less responsive for myclobutanil relative to the other conazoles and may help explain its lack of tumorigenicity after chronic exposure. Our class-based BMDL T dose-response approach also found that myclobutanil had the least number of probe sets (19 of 48) meeting the cutoff criteria. Together, these observations suggest that at 30 days myclobutanil can be identified as the least potent conazole with respect to potential hepatotumorigenicity relative to the other 4 conazoles. Traditional toxicity endpoints did not distinguish myclobutanil from propiconazole or triadimefon, 2 hepatotumorigenic conazoles . In fact, our BMDL T estimates for Cyp2b10 suggest that myclobutanil is at least as potent as propiconazole and triadimefon at activating CAR, which is possibly also reflected in increases in liver weight. Myclobutanil is also equally or more potent than triadimefon and propiconazole at inducing liver cell proliferation at 30 days, based on BMDL ISD estimates of 115, 118, and 158 mg/kg-day, respectively, when measured using the proliferation cell nuclear antibody (data not shown; modeled based on Allen et al., 2006) . BMDL ISD estimates were 12 and 10 mg/kgday for liver cell proliferation at 30 days for cyproconazole and epoxiconazole, respectively, when measured using the Ki67 antibody, a more specific cell proliferation marker than proliferation cell nuclear antigen (data not shown; modeled based on Hester et al., 2012) . Thus, in addition to dose considerations, other factors may influence the outcome of an individual key event, and these factors may affect the likelihood of progression to the next key event or the magnitude of the ultimate response (Julien et al., 2009) . As indicated above, hepatic hypertrophy is the first phenotypic key event following CAR activation (U.S. EPA, 2011b). Because increases in liver weight can be related to hepatic hypertrophy, the observation that our gene expression changes (median BMDL T ) correlated well to potency for induction of hepatic hypertrophy (ie, BMDL A for increased liver weight) supports the validity of this toxicogenomic approach. The factors contributing to the lack of hepatotumorigenicity associated with myclobutanil exposure in mice are unclear, given that the proposed molecular initiating event, CAR activation (based on Cyp2b10 induction), and other early key events, such as increased liver weight, hepatocellular hypertrophy, and liver cell proliferation are indistinguishable for many conazoles. Despite this, our 30-day median BMDL T for our subset of genes correctly stratified these 5 conazoles according to tumorigenic potency (ie, the last key event). Further, our results are the first to couple transcriptional and apical BMDs, thereby allowing for a direct comparison of concordance and potency at low-dose exposures for key molecular and apical events across 5 members of the same class of compounds. Being less influenced by sample size and dose spacing and informing the doseresponse curve, BMD levels are preferable low-dose PODs compared with NOAEL or LOAEL values.
One of the uncertainties in the present assessment is the observation that the 30-day median BMDL T value of 9 mg/kgday for cyproconazole was above the chronic BMDL A of 2 mg/ kg-day for hepatocellular adenoma or carcinoma (combined). Time-course apical BMD modeling for proposed key events, such as hepatocyte hypertrophy and hepatocyte lipid content of marked severity at 7 days, increased liver weight and reduced serum cholesterol at 30 days, and single cell necrosis and hepatocellular tumors at 18 months, suggested BMDL A values in the range of 2-4 mg/kg-day for cyproconazole (data not shown). For the other 3 tumorigenic conazoles (epoxiconazole, propiconazole, and triadimefon), the 30-day median BMDL T values were below the chronic BMDL A for the combined incidence of hepatocellular adenoma or carcinoma. Nonetheless, the 4.3-fold ratio between the 30-day median BMDL T (9 mg/kg-day) and chronic BMDL A (2.1 mg/kg-day) for hepatocellular tumors for cyproconazole falls within the existing 10-fold uncertainty factor commonly used to account for extrapolation from a less-than-lifetime to a lifetime (ie, chronic) exposure duration (U.S. EPA, 2002) . Adopting the 30-day median BMDL T values directly as PODs for quantitative risk assessment of nongenotoxic carcinogens would seem to be a feasible approach for the 3 other tumorigenic conazoles (epoxiconazole, propiconazole, and triadimefon), particularly considering that other uncertainty factors, such as interspecies and intraspecies extrapolation and database deficiencies, can also be considered. Just as traditional uncertainty factor categories identify areas of uncertainty in the dose-response analysis (U.S. EPA, 2002) , the incorporation of toxicogenomic data into quantitative risk assessment, particularly when extrapolating a short-term transcriptional POD to derive an acceptable exposure level for long-term exposure will be associated with some degree of uncertainty or variability. Transcriptomic-to-phenotypic extrapolation uncertainty has not been addressed in the published literature, perhaps because characterization of uncertainty in the risk assessment process does not occur until a POD is established. Until recently, methods to estimate a low-dose POD for a critical effect at the molecular level were not available. Our approach of comparing the concordance of transcriptional and apical BMD estimates could be used to inform both potency and the magnitude of transcriptomic-to-phenotypic extrapolation uncertainty. Of note, our 30-day median BMDL T values were within 10-fold of the chronic BMDL values for tumors. This approach can help prioritize chemicals for future testing and may lead to more expeditious and feasible decision making. In traditional risk assessments based on chronic rat and mouse bioassay results, the most sensitive target organ was the liver in mice for cyproconazole, epoxiconazole, and propiconazole, but for triadimefon and myclobutanil, the rat central nervous system and testes, respectively, were the most sensitive target tissues (U.S. EPA, 2000 EPA, , 2006a EPA, ,b,c, 2008 .
In conclusion, the ability to couple transcriptional and apical dose responses after short-term exposures is consistent with the 21st century vision for more efficient risk assessment with reduced animal testing (NRC, 2007a) . Our chemical class and key event-based concordance analyses using BMDL T and BMDL A at 30 days informed low-dose potency for a class of chemicals that are believed to share a common tumorigenic MOA. Although traditional toxicity endpoints could not distinguish tumorigenic from nontumorigenic conazoles at 30 days, our median BMDL T values corresponded well to tumorigenic potency on a miligram per kilogram day basis with cyproconazole > epoxiconazole > propiconazole > triadimefon > myclobutanil (nontumorigenic) and were within one-half order of magnitude of BMDL A values for liver tumors. When the magnitude of transcriptomic-to-phenotypic extrapolation uncertainty, a critical element to toxicogenomic-driven quantitative risk assessment, can be more fully characterized, a low-dose transcriptional POD estimated from a short-term exposure may serve as the basis of a quantitative risk assessment of long-term exposure. This approach can also help prioritize chemicals for future testing and may aid in distinguishing between tumorigenic and nontumorigenic compounds in the absence of traditional chronic rodent bioassays.
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